Filter
633
Text search:
drug
formulations
Featured
89
187
Language
Document type
319
148
85
39
15
11
8
2
2
1
1
1
Countries
48
26
22
16
16
12
11
11
10
9
9
9
8
8
8
7
7
7
7
7
6
5
5
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
242
108
32
30
19
14
8
Toolboxes
90
62
50
41
34
33
15
15
14
10
8
7
5
5
4
4
4
3
3
2
2
2
2
STATUTORY INSTRUMENTS | SUPPLEMENT No. 8 28th March, 2014 | STATUTORY INSTRUMENTS SUPPLEMENT | to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 | Printed by UPPC, Entebbe, by Order of the Government. | STATUTORY INSTRUMENTS | 2014 No. 29.
Antimicrobial resistance is a global crisis that threatens a century of progress in health and achievement of the Sustainable Development Goals. There is no time to wait. Unless the world acts urgently, antimicrobial resistance will have disastrous impact within a generation.
This guide to local production of WHO-recommended handrub formulations is separated into two discrete but interrelated sections:
Part A provides a practical guide for use at the pharmacy bench during the actual preparation of the formulation. Use
...
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Guidelines for the production of extemporaenous formulations and hospital based sterile preparations
In order to streamline and effectively control compounding of medicinal products in hospitals and pharmacies, these Guidelines for Production of Extemporaneous and Hospital Based Sterile Preparations has been crafted. The purpose of these guidelines therefore is to assist pharmacists in
...
UN, international agencies and experts released a groundbreaking report demanding immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis.
If no action is taken - warns the UN Ad hoc Interagency Coordin
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
